New stock news | Annoying Uda re-applies to Hong Kong Stock Exchange, cumulative losses exceed 460 million yuan during the reporting period.

According to the disclosure by the Hong Kong Stock Exchange on September 30th, Annoroad Gene Technology (Beijing) Co., Ltd. (referred to as Annoroad) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with Bank of Communications International and GUOTAI JUNAN Securities as its joint sponsors. The company had previously submitted a listing application to the Hong Kong Stock Exchange on March 25th. The prospectus shows that Annoroad specializes in IVD medical devices and omics life science research services based on molecular diagnostics, as well as specialized in NGS-based prenatal testing IVD products. The company's clinical sequencing solutions include self-produced IVD test kits based on genetic sequencing, genetic sequencers, bioinformatics analysis software, as well as technical support and laboratory design services. The company's clients mainly include hospitals accredited for prenatal diagnosis and independent clinical laboratories (ICL). These institutional clients purchase the company's IVD products, and the company charges fees based on the number and type of products purchased by these clients. The company's NIPT test kits (designed to detect the three most common chromosome disorders, including trisomy 21, 18, and 13) obtained class III medical device certificates in 2017 and established a market position in the prenatal testing market. According to data from Zhoushi Consulting, based on sample testing volume, the company ranked second in the Chinese NIPT market in 2024, with market shares increasing in 2022, 2023, and 2024 at 11.6%, 12.1%, and 15.5% respectively. Additionally, based on revenue, the company ranked third in the Chinese NIPT market, with a market share of 14.6%. The company provides two types of life science sequencing solutions: clinical sequencing solutions and research sequencing solutions. In the clinical sequencing solutions business line, the company first purchases reagents and equipment components from upstream suppliers. Then, it develops and sells IVD test kits, proprietary genetic sequencers, and bioinformatics software to hospitals and independent clinical laboratory through direct sales or distributors. Currently, the company mainly sells two types of IVD test kits approved by the National Medical Products Administration for reproductive health sequencing. In the research sequencing solutions business line, the company purchases genetic sequencers, test kits, and other equipment from upstream sequencing equipment suppliers, providing six types of research sequencing solutions to academic institutions, research organizations, and corporate clients. These solutions are mainly used in omics research in fields such as agriculture, forestry, animal husbandry, and fisheries, providing key insights into life sciences. As of September 23, 2025, the company has three production plants in China, mainly producing test kits and sequencers. During the reporting period, the combined annual production capacity of the production plants was 40 NextSeq 550AR sequencers and 48,000 test kits. Furthermore, due to the continuous advancement of genetic sequencing technology and the evolving demand in life science research, the market for life science sequencing solutions in which the company operates is highly competitive and rapidly evolving. The company continues to face competition from many participants, including leading domestic and foreign companies offering similar comparable products and services. Financially, for the six months ended on June 30th in 2022, 2023, 2024, and 2025, Annoroad's continuous operating revenue was approximately 435 million yuan, 475 million yuan, 518 million yuan, and 269 million yuan respectively, with annual losses of approximately 67 million yuan, 240 million yuan, 126 million yuan, and 29 million yuan.